Progenics Pharmaceuticals Announces Presentations on AZEDRA® (iobenguane I 131) and its Prostate Cancer Programs at the 30th...
October 16 2017 - 4:30PM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and imaging analytical tools for
targeting and treating cancer, announced today that data from
several of the Company’s development programs will be presented in
oral sessions at the 30th Annual Congress of the European
Association of Nuclear Medicine (EANM), which is being held in
Vienna, Austria from October 21 through 25, 2017.
Presentation details are as
follows:Date & Time: Sunday, October
22, 2017, 2:30 PM - 4:00 PM local timeSession
Title: 407 - Clinical Oncology - Rapid Fire Session:
ProstateSession Type: Oral Abstract Presentation
OP-119, OP-127Title: “Tc-99-MIP-1404 Imaging for
the Detection of PSMA-Positive Lesions. A Pilot Study in 380
Patients with Histologically Confirmed Prostate
Cancer”Title: “First Clinical Experience with
Ultra-High Resolution Multi-Focal Collimators for Tc-99m- PSMA
Imaging”
Date & Time: Sunday,
October 22, 2017, 4:30 PM - 6:00 PM local timeSession
Title: 507 - Clinical Oncology: NET, a
Classic!Session Type: Oral Abstract
PresentationTitle: “AZEDRA® (iobenguane I 131) in
Patients with Malignant and/or Recurrent Pheochromocytoma/
Paraganglioma (PPGL): Overall Tumor Response Assessment”
Date & Time: Wednesday,
October 25, 2017, 8:00 AM – 9:30 AM local timeSession
Title: 1607 – Clinical Oncology: Anything
GoesSession Type: Oral Abstract
PresentationTitle: “Convolutional neural networks
for segmentation of 49 selected bones in CT images show high
reproducibility”
About ProgenicsProgenics
develops innovative medicines and other technologies to target and
treat cancer. Progenics' pipeline includes: 1) therapeutic agents
designed to precisely target cancer (AZEDRA® and 1095), 2)
PSMA-targeted imaging agents for prostate cancer (1404 and PyL™),
and 3) imaging analysis tools. Progenics' first commercial product,
RELISTOR® (methylnaltrexone bromide) for opioid-induced
constipation, is partnered with Valeant Pharmaceuticals
International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward-looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations, such as the Phase 3
clinical program for 1404; our ability to successfully develop and
commercialize the products of EXINI Diagnostics AB; the
unpredictability of the duration and results of regulatory review
of New Drug Applications (NDA) and Investigational NDAs, including
our NDA for AZEDRA; market acceptance for approved products; the
effectiveness of the efforts of our partners to market and sell
products on which we collaborate and the royalty revenue generated
thereby; generic and other competition; the possible impairment of,
inability to obtain and costs of obtaining intellectual property
rights; possible product safety or efficacy concerns, general
business, financial, regulatory and accounting matters, litigation
and other risks. More information concerning Progenics and such
risks and uncertainties is available on its website, and in its
press releases and reports it files with the U.S. Securities and
Exchange Commission. Progenics is providing the information in this
press release as of its date and, except as expressly required by
law, Progenics disclaims any intent or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Please follow us on
LinkedIn®. Information on or accessed through our website or social
media sites is not included in the company's SEC filings.
(PGNX-F)
Contact:
Melissa Downs Investor Relations (646) 975-2533
mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024